NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 138)
Posted On: 05/01/2019 3:56:21 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces CEO Succession Plan
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences and other industries worldwide, today announced its CEO succession plan in light of its founder Richard T. Schumacher’s notification that he will step down as president and CEO effective September 9, 2019. Schumacher has been working with the company’s directors on leadership succession planning for many months, including the selection of its SVP & Chief Commercial Officer Bradford A. Young, PhD, MBA in November 2018. To facilitate an orderly transition in leadership, the PBIO board has identified Dr. Young as its designee to succeed Schumacher and will be working closely with Dr. Young to effectuate this transition. “PBI was founded on the vision that pressure – especially ultra-high pressure – could be safely used in the life sciences area to significantly accelerate the discovery and development of new drugs, vaccines, and diagnostics, which in turn could lead to better, higher quality, less expensive, and more widely available healthcare” PBIO founder Richard T. Schumacher said in the news release. “My 15 years as CEO has overseen an exciting, successful, and sometimes challenging journey, as is often the case when driving market acceptance of paradigm-shifting technology platforms. I believe we are very close to achieving success around the original vision for PBI, and I am extremely excited over the prospects for our new BaroFold and Ultra Shear Technology businesses. Nonetheless, as I will be seventy years old in August 2020, I have worked closely with the Board to prepare for a strong and orderly transition in leadership as we enter this new growth phase. I am convinced that PBI is now poised for success thanks to the depth and dedication of our senior management and support teams. The addition of Dr. Young to our team has brought highly relevant scientific experience, knowledge, and vision, combined with his business acumen and leadership qualities that I believe will be pivotal in propelling the Company forward for decades to come.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences and other industries worldwide, today announced its CEO succession plan in light of its founder Richard T. Schumacher’s notification that he will step down as president and CEO effective September 9, 2019. Schumacher has been working with the company’s directors on leadership succession planning for many months, including the selection of its SVP & Chief Commercial Officer Bradford A. Young, PhD, MBA in November 2018. To facilitate an orderly transition in leadership, the PBIO board has identified Dr. Young as its designee to succeed Schumacher and will be working closely with Dr. Young to effectuate this transition. “PBI was founded on the vision that pressure – especially ultra-high pressure – could be safely used in the life sciences area to significantly accelerate the discovery and development of new drugs, vaccines, and diagnostics, which in turn could lead to better, higher quality, less expensive, and more widely available healthcare” PBIO founder Richard T. Schumacher said in the news release. “My 15 years as CEO has overseen an exciting, successful, and sometimes challenging journey, as is often the case when driving market acceptance of paradigm-shifting technology platforms. I believe we are very close to achieving success around the original vision for PBI, and I am extremely excited over the prospects for our new BaroFold and Ultra Shear Technology businesses. Nonetheless, as I will be seventy years old in August 2020, I have worked closely with the Board to prepare for a strong and orderly transition in leadership as we enter this new growth phase. I am convinced that PBI is now poised for success thanks to the depth and dedication of our senior management and support teams. The addition of Dr. Young to our team has brought highly relevant scientific experience, knowledge, and vision, combined with his business acumen and leadership qualities that I believe will be pivotal in propelling the Company forward for decades to come.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼